Alloimmunization as a strategy for vaccine design against HIV/AIDs

AIDS Research and Human Retroviruses

Volumn 16, Issue 4, 2000, Pages 309-313

  Lehner, Thomas ^a   Shearer, Gene M ^b,e   Hackett, Charles J ^c   Schultz, Alan ^c,d   Sharma, Opendra K ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d International AIDS Vaccine Initiative   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOIMMUNIZATION; CELL STIMULATION; CONFERENCE PAPER; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; HIV INFECTIONS; HLA ANTIGENS; HUMANS; IMMUNIZATION; ISOANTIGENS;

EID: 0034051618     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309188     Document Type: Conference Paper

References (52)

1. 1. Shearer GM, Clerici M, and Dalgleish A: Alloimmunization as an AIDS vaccine? Science 1993;262:161-162. [Letter]
2. 2. Shearer GM, Pinto LA, and Clerici M: Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Immunol Today 1999;20:66-71.
3. 3. Clerici M, DePalma L, Roilides E, Baker R, and Shearer GM: Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest 1993;91:2829-2836.
4. 4. MacDonald KS, Embree J, Njenga S, Nagelkerke NJ, Ngatia I, Mohammed Z, Barber BH, Ndinya-Achola J, Bwayo J, and Plummer FA: Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998;177:551-556.
5. 5. Arthur LO, Bess JW Jr, Sowder RC II, Benveniste RE, Mann DL, Chermann JC, and Henderson LE: Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 1992;258:1935-1938.
6. 6. Frank I, Stoiber H, Godar S, Stockinger H, Steindl F, Katinger HWD, and Dierich MP: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611-1620.
7. 7. Golding H, Shearer GM, Hillman K, Lucas P. Manischewitz J, Zajac RA, Clerici M, Gress RE, Boswell RN, and Golding B: Common epitope in HIV I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV-infected individuals. J Clin Invest 1989; 83:1432-1435.
8. 8. Habeshaw J, Hounsell E, and Dalgleish A: Does the HIV envelope induce a chronic graft-versus-host-like disease? Immunol Today 1992;13:207-210.
9. 9. Stott EJ: Anti-cell antibody in macaques. Nature (London) 1991;353:393.
10. 10. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992;255:292.
11. 11. Wang Y, Tao L, Mitchell E, Bravery C, Berlingieri P, Armstrong P, Vaughan R, Underwood J, and Lehner T: Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nature Med 1999;9: 1004-1009.
12. 12. Pinto LA, Sharpe S, Cohen DI, and Shearer G: Alloantigen-stimulated anti-HIV activity. Blood 1998;92:3346-3354.
13. 13. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, and Daniel MD: Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA 1989;86:6353-6357.
14. 14. Murphey-Corb M, Martin LN, Davison-Fairburo B, Montelara RC, Miller M, West M, Ohkawa S, Baskin GB, Zhang JY, and Putney SD: A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-1297.
15. 15. Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dickover R, Luciw PA, and Jennings MB: Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990;6:1239-1246.
16. 16. Hunsmann G, Dormont D, LeGrand R, Cranage M, Greenaway P, Stahl-Hennig C, Rossi G, Verani P, Stott J, Kitchin P, Osterhaus A, DeVries P, Kurth R, Norley S, Heeney J, Biberfield G, and Putkonen P: Protection of macaques against simian immunodeficiency virus infection with activated vaccines. Comparison of adjuvants, doses and challenge ciruses. Vaccine 1995;13:295-300.
17. 17. Stott EJ, Chan WL, Mills KH, Page M, Taffs F, Cranage M, Greenaway P, and Kitchin P: Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990;336:1538-1541.
18. 18. Stott EJ, et al.: Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. Neuvieme Colloque des Cent Gardes 1994;219-224.
19. 19. Arthur LO, Bess JW Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, and Benveniste RE: Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995;69:3117-3124.
20. 20. Chan WL, Rodgers A, Grief C, Almond N, Ellis S, Flanagan B, Silvera P, Bootman J, Stott J, and Kent K: Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS 1995;9: 223-228.
21. 21. Bastiani L, Laal S, Kim M, and Zolla-Pazner S: Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997;5:3444-3450.
22. 22. Polyanskaya N, Sharpe S, Cook N, Leech S, Banks J, Dennis M, Hall G, Stott J, and Cranage M: Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retroviruses 1997; 13:923-931.
23. 23. Luscher MA, Dela Cruz CS, MacDonald KS, and B arber BH: Comment on: AIDS Res Hum Retroviruses 1997;13:923-931. AIDS Res Hum Retroviruses 1998;14:541-544.
24. 23. Luscher MA, Dela Cruz CS, MacDonald KS, and B arber BH: Comment on: AIDS Res Hum Retroviruses 1997;13:923-931. AIDS Res Hum Retroviruses 1998;14:541-544.
25. 24. Dela Cruz CS, Chamberlain J, MacDonald K, and Barber BH: Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization. Vaccine 1999;17:2479-2492.
26. 25. Chan WL, Rodgers A, Hancock RD, Taffs F, Kitchin P, Farrar G, and Liew FY: Protection of simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med 1992;176:1203-1207.
27. 26. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LA, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, and Kitchin P: Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993;9:13-22.
28. 27. Bergmeier LA, Walker J, Tao L, Cranage M, and Lehner T: Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology 1994;83:213-220.
29. 28. Wang Y, Tao L, Mitachell E, Bogers WJM, Doyle C, Bravery CA, Bergmeier LA, Kelly CG, Heeney JL, and Lehner T: Generation of CD8 suppressor factor and β-chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus in macaques. Proc Natl Acad Sci USA 1998;95: 5223-5228.
30. 29. Moriuchi H, Moriuchi M, and Fauci AS: Induction of HIV-1 replication by allogeneic stimulation. J Immunol 1999;162:7543-7548.
31. 30. Lehner T, Wang Y, Doyle C, Tao L, Bergmeier LA, Mitchell E, Bogers WJM, Heeney J, and Kelly CG: Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur J Immunol 1999;29:2427-2435.
32. 31. Lehner T: In preparation (2000).
33. 32. Coulam CB, Collins J, Scott JR, and Schlesselman JS: Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32: 55-72.
34. 33. Plautz GE, Yang ZY, Wu By, Gao X, Huang L, and Nabel GJ: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645-4649.
35. 34. Hu H-M, Urba WJ, and Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998; 161: 3033-3041.
36. 35. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989; 84: 1892-1899.
37. 36. Grene E, Newton DA, Brown EA, Berzofsky JA, Gattoni-Celli S, and Shearer GM: Semi-allogeneic cell hybrids as immunotherapy for AIDS. Submitted (2000).
38. 37. Shearer GM, Bernstein DC, Tung KSK, Via CS, Redfield R, Salahuddin SZ, and Gallo RC: A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986; 137: 2514-2521.
39. 38. Clerici M, Stocks NI, Zajac RA, Boswell N, Via CS, and Shearer GM: Circumvention of defective CD4 T helper cell function in HIV-infected individuals by stimulation with HLA alloantigens. J Immunol 1990; 144: 3266-3271.
40. 39. Blazevic V, Pinto LA, Trubey CM, and Shearer GM: Analysis of alloantigen-induced help for virus-specific cytotoxic T lymphocytes. J Leuk Biol 2000; in press.
41. 40. Dudhane A, Conti B, Orlikowsky T, Wang ZQ, Mangla N, Gupta A, Wormser GP, and Hoffmann MK: Monocytes in HIV type 1-infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. AIDS Res Hum Retroviruses 1996; 12: 885-892.
42. 41. Kumar A, Angel JB, Aucoin S, Creery WD, Daftarian MP, Cameron DW, Filion L, and Diaz-Mitoma F: Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Clin Exp Immunol 1999; 117: 84-91.
43. 42. Lindenmann J: Viruses as immunological adjuvants in cancer. Biochim Biophys Acta 1974; 355: 49-75.
44. 43. Kim BS: Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma. J Immunol 1979; 123: 739-744.
45. 44. Payelle B, Poupon M-F, and Lespinats G: Adoptive transfer of immunity induced by semi-allogeneic hybrid cells, against a murine fibrosarcoma. Int J Cancer 1981; 27: 783-788.
46. 45. Toffaletti DL, Darrow TL, and Scott DW: Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids. J Immunol 1983; 130: 2982-2986.
47. 46. Souberbielle BE, Westby M, Ganz S, Kayaga J, Mendes R, and Morrow WJW: Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther 1998; 5: 1447-1454.
48. 47. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
49. 48. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, and Dellabona P: Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
50. 49. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, and Chang AE: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388-15393.
51. 50. Newton DA, McClay EF, Romano C, and Gattoni-Celli S: Irradiated semi-allogeneic cell hybrids as therapeutic vaccines for cancer. J Immunother 1999 (in press).
52. 51. Keene JA and Forman J: Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982; 155: 768-782.